CCDC13: A Potential Drug Target and Biomarker for Neurological Disorders

Target Name: CCDC13

NCBI ID: G152206

CCDC13

Other Name(s): Coiled-coil domain-containing protein 13 | CCD13_HUMAN | FLJ25467 | coiled-coil domain containing 13 | Coiled-coil domain containing 13

CCDC13: A Potential Drug Target and Biomarker for Neurological Disorders

CDC13, or Coiled-coil domain-containing protein 13, is a protein that has been identified in various neurological disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. It is a highly conserved protein that is expressed in most tissues and cells in the body. The protein is known to play a crucial role in the development and progression of these disorders, which has led to its potential as a drug target or biomarker.

CDC13 functions as a transmembrane protein that is involved in various signaling pathways, including the cAMP/protein kinase A (PKA) signaling pathway. This pathway is involved in the regulation of a wide range of cellular processes, including cell growth, differentiation, and survival.

In the context of neurological disorders, the cAMP/PKA signaling pathway is disrupted, leading to the development of pathological conditions. The disruption of this pathway has been implicated in the development of numerous neurological disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.

CDC13 has been shown to play a role in the regulation of the cAMP/PKA signaling pathway in various neurological disorders. For example, studies have shown that DCP13 is involved in the regulation of neurotransmitter release from neurons, which is critical for the function of the nervous system. Additionally, studies have shown that DCP13 is involved in the regulation of the growth and survival of neural cells, which is crucial for the development and progression of neurological disorders.

As a potential drug target, DCP13 can be targeted with small molecules or antibodies that can modulate its activity. For example, small molecules that can inhibit the activity of DCP13 have been shown to be effective in treating neurological disorders, including Alzheimer's disease and Parkinson's disease. Similarly, antibodies that can selectively bind to DCP13 have been shown to be effective in treating these disorders.

In addition to its potential as a drug target, DCP13 also has the potential as a biomarker for the diagnosis and progression of neurological disorders. The cAMP/PKA signaling pathway is a well-established biomarker for the diagnosis of neurological disorders, and DCP13 is involved in this pathway. Therefore, measuring the activity of DCP13 has the potential to provide valuable information about the severity and progression of these disorders.

Conclusion

CDC13 is a protein that has been implicated in the development and progression of numerous neurological disorders. Its function as a transmembrane protein involved in the cAMP/PKA signaling pathway makes it a potential drug target or biomarker. Further research is needed to fully understand the role of DCP13 in neurological disorders and to develop effective treatments.

Protein Name: Coiled-coil Domain Containing 13

Functions: Required for primary cilia formation and promotes the localization of the ciliopathy protein BBS4 to both centriolar satellites and cilia

The "CCDC13 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCDC13 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets